Biogen Idec Oncology Pipeline. Greg Reyes, MD, PhD SVP, Oncology Research & Development

Size: px
Start display at page:

Download "Biogen Idec Oncology Pipeline. Greg Reyes, MD, PhD SVP, Oncology Research & Development"

Transcription

1 Biogen Idec Oncology Pipeline Greg Reyes, MD, PhD SVP, Oncology Research & Development March 25, 2009

2 Biogen Idec Strategy in Lymphoma / Leukemia CLL RITUXAN NHL FC-RITUXAN GA101 RITUXAN-CVP RITUXAN-CHOP FCR-Lumiliximab Relapsed CLL R-Galiximab Relapsed NHL 2

3 RITUXAN Chimeric mab That Binds To and Kills CD20-Expressing Cells Rituxan ADCC Macrophage, monocyte, or natural killer cell FcγRII, FcγRIII CD20 Cell lysis B cell CDC MAC Cell lysis Apoptosis 2009: RITUXAN submissions in Chronic Lymphocytic Leukemia REACH Study: Relapsed CLL CLL8 Study: Frontline CLL Golay et al. Blood. 2000;95:3900; Reff et al. Blood. 1994;83:435; Byrd et al. Blood. 2002;99: ADCC = antibody-dependent cellular cytotoxicity CDC = complement-dependent cytotoxicity

4 REACH and CLL8 Study Design in CLL Screening REACH: Relapsed CLL ~550 patients (First relapse of disease); 90 sites, 17 countries Randomize R-FC x 3 cycles (q 4 weeks) Restage FCR x 3 cycles (q 4 weeks) Binet B,C ~820 patients; (No prior treatment) FC x 3 cycles (q 4 weeks) PD- Off study FC x 3 cycles (q 4 weeks) CLL8: Frontline CLL Screening 4

5 REACH Primary Endpoint: K-M Plot of PFS Proportion Event Free FCR FC Median follow-up 25.3 months Median PFS FC= 21.7 months FCR= 26.6 months HR = 0.76, p=0.02 (IRC) Months since randomization 5

6 CLL8 Primary Endpoint: K-M Plot of PFS Median Follow-up 25.5 Months Median PFS: FC= 32.3 months FCR =42.8 months p=

7 Summary: RITUXAN for the Treatment of CLL REACH Relapsed CLL Median PFS = 21.7 months for FC vs months for FCR (p=0.02 by IRC) CLL8 Frontline CLL Median PFS =32.3 months for FC vs months for FCR (p= ) Both studies significant in both CR and ORR No new or unexpected safety signals consistent with RITUXAN safety profile from other studies MABTHERA (trade name for RITUXAN in the Europe) approved for the front-line treatment of CLL in combination with FC in February 2009 Dual submission of both CLL8 and REACH planned in the US by mid

8 GA101: Third generation anti-cd20 program Preclinical data suggest that GA101 may be better than RITUXAN Increased apoptosis and ADCC Higher affinity for FcγRIIIa receptors In several models, prevents regrowth compared with RITUXAN which temporarily suppresses More effective in depleting B-cells Both degree and duration of depletion in NH primates Goal: Develop a best-in-class anti-cd20 therapy leading to a significant improvement in clinical outcomes for patients with B cell malignancies. 8

9 B Cell Depletion in NH Primates: GA101 vs. RITUXAN 200 Inguinal ( Lymph ) Nodes Abs numbers/mg wt.(x10e3) Vehicle Rituximab (2 x 10 mg/kg) GA101 (2 x 10 mg/kg) GA101 (2 x 30 mg/kg) 0 Baseline Days After Dosing Umana et al., 2007 ASH Meeting, Atlanta, GA 9

10 CD23 and Lumiliximab Mechanism of Action Human constant Regions (IgG1 kappa isotype) Macaque variable regions CD23 Overview CD23 is the low affinity receptor for IgE (FcεRII) Functions to regulate IgE synthesis CD23 is highly expressed and abnormally regulated on CLL cells Lumiliximab is a monoclonal antibody that binds human CD23 with high affinity (Kd = 0.12nM) Lumiliximab Mechanism of Action Predominant MOA is apoptotic cell death via the intrinsic mitochondrial pathway Induces down-regulation of anti-apoptotic proteins including Bcl-2, Bcl-XL, Mcl-1, and XIAP in CLL cells Enhances the apoptotic activity of other anticancer drugs from a number of different classes Adapted from Gould and Sutton Nat. Rev. Immunol

11 Lumiliximab Enhances Apoptosis when Combined with Fludarabine or RITUXAN In Vitro Efficacy (SKW 6.4 cells plus cross-linker) In Vivo Efficacy (disseminated lymphoma SCID mouse model) % Apoptotic Cells Caspase-3 activation (%) Untreated Untreated Isotype Ctrl Isotype Ctrl Lumiliximab Lumiliximab Fludarabine Lumi + Flu RITUXAN Lumi + Ritux Lumiliximab + fludarabine Lumiliximab + RITUXAN Dose (μg/ml) 11 Survival (%) Survival (%) Lumiliximab + Fludarabine Lumiliximab (200 μg) Fludarabine (50 mg/kg) Control Days Following Implant Control Lumiliximab + RITUXAN RITUXAN (200 μg) Lumiliximab (200 μg) Days Following Implant

12 Lumiliximab Clinical Program Lumiliximab Monotherapy Ph 1 dose escalation in Relapsed CLL Well-tolerated at all doses studied Evidence of clinical activity in majority of patients Recommended dose for future studies, 500 mg/m2 At doses 375 mg/m2, CD23 sites on CLL cells were saturated 500 mg/m2 dose resulted in longest duration of receptor saturation No relationship between dose and adverse events Lumiliximab +/- FCR Ph 1/2 and 2/3 (LUCID) in Relapsed CLL; Ph 2 in CLL Frontline (LIFT) Rationale for FCR combination regimen: In vitro and in vivo studies demonstrated improved cytotoxic activity of lumiliximab in combination with fludarabine or rituximab Fludarabine, cyclophosphamide and rituximab (FCR) has emerged as the standard of care for the treatment of CLL. Ph I/II study demonstrated a 52% complete response (CR) in relapsed CLL, more than twice the CR rate of FCR alone in historical controls, 12

13 Phase II/III, Lumiliximab in Combination With FCR (LUCID) Patient Eligibility (n=900) Relapsed CD23+/CD20+ B-cell CLL 1-2 prior therapies Rai stage III/IV Stage I/II with disease progression Patients not refractory to FC, FR or FCR 6 cycles Lumiliximab + FCR FCR Phase II Complete response endpoint Enrollment complete 390 Pts Phase III Progression-free survival endpoint Strategy for accelerated approval: CR and trend in PFS 13 Note: Study

14 Lumiliximab (anti-cd 23 mab) Molecule Molecular Hypothesis First-in-Class Monoclonal Antibody Targeting CD23 Demonstrated apoptotic cell death as primary MOA and may be potentially effective at overcoming resistance generally seen in CLL Enhanced apoptotic activity in combination with common CLL therapies, fludarabine and rituximab Therapeutic Hypothesis Addition of a well-tolerated pro-apoptotic agent to current SOC treatment will offer greater efficacy without additional toxicity.. Potential Indications Stage Chronic lymphocytic leukemia, small lymphocytic lymphoma Preclinical combination studies ongoing Global Registrational Phase 2/3 trial ongoing in relapsed CLL. Lumiliximab as a critical component of standard therapy, essential for maximizing response and thereby extending longevity and Quality of Life in patients with CLL 14

15 CD80 Expressed on NHL tumor cells Role in Regulating Balance Between Immune Activation and Suppression Background Transmembrane glycoprotein Member of the B7 ligand family (B7.1) 1 Involved in activation and regulation of T- cells 2 Transiently expressed on activated B- cells and antigen presenting cells 3 Plays a role in the regulation and activation of normal and malignant B- cells 1 Therapeutic Hypothesis In addition to direct ADCC-mediated killing of CD80-positive malignant B-cells, galiximab may also inhibit tumor progression by targeting non-malignant, CD80-expressing cells present in the tumor microenvironment (e.g., macrophages, dendritic cells). This may result in an alteration of the cellular composition and/or cytokine profile within the tumour microenvironment that favors inhibition of tumor progression Constitutively expressed on malignant B- cells and Reed-Sternberg cells 4 1. Suvas S et al. J Biol Chem 2002;277: Guinan EC et al. Blood 1994;84: Chambers CA & Allison JP. Curr Opin Cell Biol 1999;11: Munro JM et al. Blood 1994;83:

16 Enhanced Anti-Tumor Activity and Improved Survival in Galiximab Immuno-chemo Combination Therapy SKW disseminated human lymphoma model 100 Gali+Ritux+Doxo Percent Survival Doxo Neg Control IgG1 Doxo injections Antibody injection Ritux Gali + Ritux Ritux + Doxo Days Post Implant Hariharan et al. J Clin Onc 2007;25(18S): abstract 3040; T. Murphy study G-3 16

17 Galiximab Clinical Trials in Lymphoma Relapsed Follicular NHL Monotherapy, Ph I/II in Relapsed Follicular NHL (114-20) Clean safety profile; 4/37 (11%) ORR; Late conversions of PRs to CRs Galiximab + RITUXAN, Ph I/II in Relapsed Follicular NHL (114-21) No increased toxicity; 12.2 month Median PFS compared to 9.4 months for historical RITUXAN monotherapy Galiximab + RITUXAN, Ph III in Relapsed f NHL (114NH301, ongoing) 245 subjects randomized as of March 2, 2009 Galiximab + RITUXAN, Ph III in Relapsed f NHL re-treatment (114NH302, ongoing) Frontline NHL Monotherapy, Ph I (MOA) in Frontline Follicular NHL (114NH103) Galiximab + RITUXAN, Ph II in Frontline f NHL (CALGB-sponsored, 50402, ongoing) Ongoing: 70% ORR, 44% CR/CRU, 12 month DFS 87%; Delayed responses in >15% of PR to CR conversion after 9 mos. of treatment Hodgkin s Monotherapy, Ph II in Relapsed Hodgkin s disease (CALGB-sponsored, 50602, ongoing) 17

18 Phase I/II Galiximab Monotherapy: Study Single Agent Responses Delayed time to best response seen in 4 patients Phase I/II dose-escalating study 4 weekly IV infusions (125, 250, 375, or 500 mg/m2) 37 patients treated (9 received the commercial dose of 500 mg/m2) Overall response rate of 11% (4 of 37 patients) 375 mg/m2 (N = 21): 2 CRs, 1 Baseline Study Month 5 Study Month 12 PR; 500 mg/m2 (N = 10): 1 PR Delayed time to best response seen in the four responders (at 3, 6, 9 and 12 months) Duration of response was 22.7 months 18

19 Efficacy Results (Galiximab + RITUXAN) vs. RITUXAN Event-Free Survival (%) C Ph 1/2 in Relapsed NHL (114-21) Historical Control: RITUXAN monotherapy median EFS = 9.4 mo. Galiximab + RITUXAN median EFS = 12.2 mo Time (Months) Median Age (yrs) Male Stage III/IV Disease Largest Tumor (cm) Median Max # Prior Regimens Median Max RITUXAN Naïve Galiximab + RITUXAN (500 mg/m 2 ) (N=64) % 88 % , , 9 42 % Historical RITUXAN Monotherapy (N=243) % 83 % , , 9 77 % More RITUXAN Naïve in HX control Note: Historic Rituxan EFS data are truncated at 24 months 19

20 TARGET Study (114NH301) Phase III Galiximab + RITUXAN Screening Randomization ~742 patients (First relapse of disease) 4 weekly cycles RITUXAN (375 mg/m2) + placebo RITUXAN (375 mg/m2) + galiximab (500 mg/m2) Follow-up to month 48 Conducted at 220 sites in 28 countries Nearly 250 patients randomized (more than a third of total) Primary endpoint - superiority in PFS with Galiximab + RITUXAN compared with RITUXAN 20

21 Galiximab (anti-cd 80 mab) Molecule Molecular Hypothesis Therapeutic Hypothesis Potential Indications Stage First-in-Class Monoclonal Antibody Targeting CD80 Binding to CD80 induces antibody dependent mediated cellular cytotoxicity (ADCC), synergistic with rituximab Constitutive expression on malignant B-cells and R-S cells Immune mechanisms regulating anti-tumor activity may also contribute to efficacy (APCs and activated B cells) Galiximab will have a role as adjunctive therapy for the treatment of CD80-expressing malignancies including relapsed Follicular Lymphoma based on a direct anti-tumor effect and its unique action on the tumor microenvironment Primary Indication: Relapsed follicular NHL Other: Untreated follicular NHL, DLBCL, Hodgkin s disease Phase 3 Generate rigorous mechanistic and clinical data in support of registration for Relapsed Follicular Lymphoma and establish the rationale for treatment of other CD80 expressing malignancies 21

22 Biogen Idec Oncology Pipeline Oncology RITUXAN Galiximab Lumiliximab Volociximab HSP90 Inhibitors GA101 TYSABRI Anti-IGF-1R Anti-Cripto-DM4 RAF Inhibitor Anti-Fn14 Pre-Clinical Phase 1 Phase 2 Phase 3 Market NHL & CLL (Ph 3 complete, filings 2009) NHL CLL Solid tumors Solid tumors NHL & CLL Multiple Myeloma Solid tumors Solid tumors Solid tumors Solid tumors January 2007 Pipeline 2007 and 2008 Progress 22

23 Biogen Idec Research & Development Day March 25, 2009

Update: New Treatment Modalities

Update: New Treatment Modalities ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant

More information

Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria

Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria Chronic lymphocytic Leukemia Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria georg.hopfinger@wgkk.at CLL Diagnosis and Staging Risk Profile Assessment

More information

Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial

Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the

More information

The case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.

The case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc. The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation

More information

TarGeting B-Cell Diseases

TarGeting B-Cell Diseases TarGeting B-Cell Diseases Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements

More information

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of

More information

Brad S Kahl, MD. Tracks 1-21

Brad S Kahl, MD. Tracks 1-21 I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical

More information

BTK Inhibitors and BCL2 Antagonists

BTK Inhibitors and BCL2 Antagonists BTK Inhibitors and BCL2 Antagonists Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia and Indolent Lymphoma, Peter MacCallum Cancer

More information

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus

More information

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium rituximab 10mg/ml concentrate for infusion (MabThera ) Roche (No.330/06) 10 November 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above

More information

eastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning

eastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning Results of E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Indolent B-Cell Lymphoma Michael Williams, Fangxin Hong, Brad Kahl, Randy

More information

Janssen Hematologic Malignancy Portfolio

Janssen Hematologic Malignancy Portfolio Janssen Hematologic Malignancy Portfolio Recorded Webcast: Update for Analysts and Investors January 216 Oncology 1 Safe Harbor Statement This webcast contains "forward-looking statements" as defined in

More information

*Jagiellonian University, Kraków, Poland

*Jagiellonian University, Kraków, Poland Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin s Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study Wojciech Jurczak, *

More information

COMPANY PRESENTATION. January 2019

COMPANY PRESENTATION. January 2019 COMPANY PRESENTATION January 2019 1 FORWARD-LOOKING STATEMENT This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise

More information

Clinical Pipeline Highlights

Clinical Pipeline Highlights Clinical Pipeline Highlights Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 25 MDX-7: Anti-PSMA HuMAb for Prostate Cancer Biology PSMA expressed

More information

CARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre

CARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS

More information

National Horizon Scanning Centre. Rituximab (MabThera) for chronic lymphocytic leukaemia. September 2007

National Horizon Scanning Centre. Rituximab (MabThera) for chronic lymphocytic leukaemia. September 2007 Rituximab (MabThera) for chronic lymphocytic leukaemia This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive

More information

Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates

Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia

More information

Rituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description

Rituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.96 Subject: Rituxan Hycela Page: 1 of 5 Last Review Date: September 15, 2017 Rituxan Hycela Description

More information

CLL: disease specific biology and current treatment. Dr. Nathalie Johnson

CLL: disease specific biology and current treatment. Dr. Nathalie Johnson CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck

More information

GSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017

GSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017 GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics

More information

RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA

RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin

More information

New Targets and Treatments for Follicular Lymphoma

New Targets and Treatments for Follicular Lymphoma Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,

More information

Antibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma

Antibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma Antibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma Steven I. Park, MD, 1* and Kristy L. Richards, PhD, MD 1 ABSTRACT Antibody-based immunotherapeutic agents have emerged as important

More information

CLL - venetoclax. Peter Hillmen St James s University Hospital Leeds 10 th May 2016

CLL - venetoclax. Peter Hillmen St James s University Hospital Leeds 10 th May 2016 CLL - venetoclax Peter Hillmen peter.hillmen@nhs.net St James s University Hospital Leeds 10 th May 2016 Pathophysiology of CLL: Proliferation vs Apoptosis Proliferation Apoptosis Ki-67 Expression Bcl-2

More information

Disclosures WOJCIECH JURCZAK

Disclosures WOJCIECH JURCZAK Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA

More information

Daratumumab: Uncovering a novel mechanism of action for an approved antibody therapy

Daratumumab: Uncovering a novel mechanism of action for an approved antibody therapy Daratumumab: Uncovering a novel mechanism of action for an approved antibody therapy Dr. Kate Sasser, PhD Corporate VP, Translational Research December 14 th, 2017 CD38 is ubiquitously expressed in Myeloma

More information

Venetoclax in MCL. Prof. Le Gouill Nantes Medical University, France

Venetoclax in MCL. Prof. Le Gouill Nantes Medical University, France Venetoclax in MCL Prof. Le Gouill Nantes Medical University, France Evasion of Apoptosis, or Cell Death, is 1. Resisting Cell Death 2. Sustained angiogenesis for growth and survival (primarily solid tumors)

More information

Corporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers

Corporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain

More information

AGRESSIVE LYMPHOMAS - FUTURE. Dr Stéphane Doucet CHUM

AGRESSIVE LYMPHOMAS - FUTURE. Dr Stéphane Doucet CHUM AGRESSIVE LYMPHOMAS - FUTURE Dr Stéphane Doucet CHUM What are clinical trials? Clinical trials are carefully planned research studies where the most-promising discoveries and results from laboratory studies

More information

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers

More information

Building a Leading Oncology Franchise

Building a Leading Oncology Franchise ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may

More information

Advances in CLL 2016

Advances in CLL 2016 Advances in CLL 2016 The Geoffrey P. Herzig Memorial Symposium, Louisville, KY Kanti R. Rai, MD Northwell-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Disclosures Member

More information

BR is an established treatment regimen for CLL in the front-line and R/R settings

BR is an established treatment regimen for CLL in the front-line and R/R settings Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,

More information

Update: Chronic Lymphocytic Leukemia

Update: Chronic Lymphocytic Leukemia ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8

More information

BR for previously untreated or relapsed CLL

BR for previously untreated or relapsed CLL 1 Protocol synopsis Title Rationale Study Objectives Multicentre phase II trial of bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia

More information

CHMP recommends EU approval of Roche s Gazyvaro for people with previously treated follicular lymphoma

CHMP recommends EU approval of Roche s Gazyvaro for people with previously treated follicular lymphoma Media Release Basel, 29 April 2016 CHMP recommends EU approval of Roche s Gazyvaro for people with previously treated follicular lymphoma In the pivotal study, treatment with Gazyvaro plus bendamustine

More information

NASDAQ: TGTX. J.P. Morgan Healthcare Conference January 2017

NASDAQ: TGTX. J.P. Morgan Healthcare Conference January 2017 NASDAQ: TGTX J.P. Morgan Healthcare Conference January 2017 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy

ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy European Medicines Agency Workshop on Scientific and Regulatory Challenges of Genetically Modified Cell-based Cancer Immunotherapy

More information

DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA

DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt,

More information

CAR-T cell therapy pros and cons

CAR-T cell therapy pros and cons CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research

More information

CORPORATE PRESENTATION

CORPORATE PRESENTATION CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

More information

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)

More information

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin

More information

Media Release. Basel, 7 November 2013

Media Release. Basel, 7 November 2013 Media Release Basel, November 2013 Roche s Gazyva helped people with one of the most common forms of blood cancer live significantly longer without their disease worsening compared to MabThera/Rituxan

More information

Lymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?

Lymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient? Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte

More information

State of the art: CAR-T cell therapy in lymphoma

State of the art: CAR-T cell therapy in lymphoma State of the art: CAR-T cell therapy in lymphoma 14 th annual California Cancer Consortium conference Tanya Siddiqi, MD City of Hope Medical Center 8/11/18 Financial disclosures Consultant for Juno therapeutics

More information

Update on Management of CLL. Presenter Disclosure Information. Chronic Lymphocytic Leukemia. Audience Response Question?

Update on Management of CLL. Presenter Disclosure Information. Chronic Lymphocytic Leukemia. Audience Response Question? Welcome to Master Class for Oncologists New York, NY May 14, 2010 Session 5: 4:20 PM - 5:00 PM Update on Management of CLL John C. Byrd, MD D Warren Brown Professor of Leukemia Research Professor of Medicine

More information

UBS European Conference 2013

UBS European Conference 2013 UBS European Conference 2013 Tuesday, 12 November 2013 Karl Mahler, Head of Investor Relations Stefan Frings, Oncology/Immunology Therapeutic Area Head,Roche Partnering Group: Continued strong sales growth

More information

Rituximab, recombinant for intravenous infusion (CAS registry number: ).

Rituximab, recombinant for intravenous infusion (CAS registry number: ). MABTHERA Rituximab, recombinant for intravenous infusion (CAS registry number: 174722-31-7). WARNING Use of MABTHERA may be associated with an increased risk of progressive multifocal leukoencephalopathy

More information

Rituximab in the Treatment of NHL:

Rituximab in the Treatment of NHL: New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,

More information

Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD

Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang-Mai University Outline

More information

Open questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland

Open questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific

More information

Mantle cell lymphoma An update on management

Mantle cell lymphoma An update on management Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag

More information

Linfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP

Linfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of

More information

Mathias J Rummel, MD, PhD

Mathias J Rummel, MD, PhD I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track

More information

Media Release. Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma. Basel, 22 September 2017

Media Release. Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma. Basel, 22 September 2017 Media Release Basel, 22 September 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Approval is based on phase III GALLIUM study results, which

More information

CAR-T CELLS: NEW HOPE FOR CANCER PATIENTS

CAR-T CELLS: NEW HOPE FOR CANCER PATIENTS CAR-T CELLS: NEW HOPE FOR CANCER PATIENTS Natasha Kekre, MD, MPH, FRCPC Hematologist, Blood and Marrow Transplant Program, TOH Associate Scientist, Ottawa Hospital Research Institute Assistant Professor

More information

Lymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University

Lymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies

More information

Corporate Presentation

Corporate Presentation Corporate Presentation October 2018 NASDAQ/TSX: TRIL This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking

More information

B Kahl 1, M Hamadani 2, P Caimi 3, E Reid 4, K Havenith 5, S He 6, JM Feingold 6, O O Connor 7

B Kahl 1, M Hamadani 2, P Caimi 3, E Reid 4, K Havenith 5, S He 6, JM Feingold 6, O O Connor 7 First Clinical Results of ADCT-42, a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate (ADC), in Relapsed/Refractory B-cell Lineage Non-Hodgkin Lymphoma B Kahl 1, M Hamadani 2, P Caimi 3, E Reid

More information

12 th Annual Hematology & Breast Cancer Update Update in Lymphoma

12 th Annual Hematology & Breast Cancer Update Update in Lymphoma 12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma

More information

NASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference

NASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference NASDAQ: TGTX 33 rd Annual JP Morgan Healthcare Conference January 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities

More information

NHS England. Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma

NHS England. Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma NHS England Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma NHS England Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma

More information

Immuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016

Immuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016 Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival

More information

TRANSPARENCY COMMITTEE OPINION. 8 November 2006

TRANSPARENCY COMMITTEE OPINION. 8 November 2006 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,

More information

Haemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY. Development and clinical experience Monique Minnema, hematologist

Haemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY. Development and clinical experience Monique Minnema, hematologist Haemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Development and clinical experience Monique Minnema, hematologist Consultancy for disclosures Amgen, Celgene, Jansen Cilag, BMS, Takeda Immune

More information

Daratumumab, a novel human CD38 monoclonal antibody for the treatment of B cell Non Hodgkin Lymphoma

Daratumumab, a novel human CD38 monoclonal antibody for the treatment of B cell Non Hodgkin Lymphoma Daratumumab, a novel human CD38 monoclonal antibody for the treatment of B cell Non Hodgkin Lymphoma Anna Vidal Department of Hemato Oncology IDIBAPS, Barcelona, Spain B cell lymphoid malignancies seen

More information

Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765

Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325 Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Company to Host

More information

RITUXAN (rituximab and hyaluronidase human)

RITUXAN (rituximab and hyaluronidase human) Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria

More information

Checkpoint Blockade in Hematology and Stem Cell Transplantation

Checkpoint Blockade in Hematology and Stem Cell Transplantation Checkpoint Blockade in Hematology and Stem Cell Transplantation Saad S. Kenderian, MD Assistant Professor of Medicine and Oncology Mayo Clinic College of Medicine October 14, 2016 2015 MFMER slide-1 Disclosures

More information

Chronic Lymphocytic Leukemia Update. Learning Objectives

Chronic Lymphocytic Leukemia Update. Learning Objectives Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend

More information

Nimotuzumab Paul Keane MD, FRCPC, FACP, FRC Path

Nimotuzumab Paul Keane MD, FRCPC, FACP, FRC Path Nimotuzumab Paul Keane MD, FRCPC, FACP, FRC Path Research & Development Day Wednesday April 5, 2006 Harvard Club New York City EGFR The EGFR is a member of the ErbB family of tyrosine kinase (TK) receptors

More information

Gazyva (obinutuzumab)

Gazyva (obinutuzumab) STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination

More information

Targeted Radioimmunotherapy for Lymphoma

Targeted Radioimmunotherapy for Lymphoma Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,

More information

Corporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers

Corporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Corporate Presentation November 2015 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate

More information

CLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE

CLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE FOR IMMEDIATE RELEASE CLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE Results of Studies of BEXXAR TM Therapy Show Promise

More information

OSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD

OSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin

More information

Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies

Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies David Feltquate MD, PhD Head of Early Clinical Development, Oncology Bristol-Myers Squibb, Princeton, NJ Challenges

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium ibritumomab tiuxetan (Zevalin ) No. (171/05) Schering Health Care Ltd 8 April 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

CLL & SLL: Current Management & Treatment. Dr. Peter Anglin

CLL & SLL: Current Management & Treatment. Dr. Peter Anglin CLL & SLL: Current Management & Treatment Dr. Peter Anglin Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of blood cell B lymphocyte Lymphocytic Cancer of white blood

More information

Advances in haematological malignancies focus on lymphoid disease

Advances in haematological malignancies focus on lymphoid disease Advances in haematological malignancies focus on lymphoid disease Dr Kylie Mason MBBS PhD FRACP FRCPA Haematologist Bone marrow Transplant Physician Clinician Scientist The Royal Melbourne Hospital The

More information

Chimeric An+gen Receptor (CAR) Modified T Cell Therapy: Mee#ng the Unmet Need in Follicular Lymphoma

Chimeric An+gen Receptor (CAR) Modified T Cell Therapy: Mee#ng the Unmet Need in Follicular Lymphoma Chimeric An+gen Receptor (CAR) Modified T Cell Therapy: Mee#ng the Unmet Need in Follicular Lymphoma Stephen J. Schuster, M.D. Director, Lymphoma Program & Lymphoma Translational Research, Abramson Cancer

More information

Building a Fully Integrated Biopharmaceutical Company. June 2014

Building a Fully Integrated Biopharmaceutical Company. June 2014 Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation

More information

NEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) Investor: Karl Mahler Thomas Kudsk Larsen (973)

NEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) Investor: Karl Mahler Thomas Kudsk Larsen (973) NEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) 467-6800 Investor: Karl Mahler 011 41 61 687 8503 Thomas Kudsk Larsen (973) 235-3655 Biogen Idec Contacts: Media: Christina Chan (781) 464-3260

More information

The case for maintenance rituximab in FL

The case for maintenance rituximab in FL New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P

More information

R/R DLBCL Treatment Landscape

R/R DLBCL Treatment Landscape An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,

More information

Follicular Lymphoma New Agents. Idelalisib

Follicular Lymphoma New Agents. Idelalisib Indolent Lymphoma Workshop Bologna 2017 Follicular Lymphoma New Agents Idelalisib Sven de Vos, MD, PhD Director, UCLA Lymphoma Program Los Angeles, CA Disclosures of Sven de Vos Company name Research support

More information

Il Rituximab nella ITP

Il Rituximab nella ITP Il Rituximab nella ITP Monica Carpenedo U.O.C Ematologia e TMO, Ospedale San Gerardo, Monza Burning questions about Rituximab and ITP What is the mechanism of action? What is long term effect of treatment?

More information

Clinical: Ipilimumab (MDX-010) Update and Next Steps

Clinical: Ipilimumab (MDX-010) Update and Next Steps Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy

More information

Media Release. Basel, 5 December 2016

Media Release. Basel, 5 December 2016 Media Release Basel, 5 December 2016 Roche s Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan

More information

Copyright. Tocagen Inc. Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview

Copyright. Tocagen Inc. Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview Toca 511, delivers CD prodrug activator gene selectively to cancer cells Regulatory genes Structural RRV genes CD gene Regulatory genes Toca

More information

LAG-3: Validation Of Next Generation Checkpoint Pathways

LAG-3: Validation Of Next Generation Checkpoint Pathways LAG-3: Validation Of Next Generation Checkpoint Pathways Frédéric Triebel, CO/CMO Immune Checkpoint Modulation & Combination Therapies April 13, 2016 London, UK. 1 AX:PRR; NADAQ:PBMD Notice: Forward Looking

More information

Managing patients with relapsed follicular lymphoma. Case

Managing patients with relapsed follicular lymphoma. Case Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell

More information

Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division

Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division University of Virginia Cancer Center The Clinical Continuum of CLL Early asymptomatic

More information

Dr. C. Tom Kouroukis. New and upcoming treatments for Lymphoma

Dr. C. Tom Kouroukis. New and upcoming treatments for Lymphoma Dr. C. Tom Kouroukis New and upcoming treatments for Lymphoma New and upcoming treatments for Lymphoma Dr. Tom Kouroukis Hamilton Convention Centre November 23, 2013 Overview Importance and design of clinical

More information